

ORASURE TECHNOLOGIES INC  
Form 8-K  
December 20, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**  
**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 20, 2005

OraSure Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)

|  |                  |                     |
|--|------------------|---------------------|
| <u>Delaware</u>                          | <u>001-16537</u> | <u>36-4370966</u>   |
| (State or Other Jurisdiction             | (Commission      | (I.R.S. Employer    |
| of Incorporation)                        | File Number)     | Identification No.) |
| 220 East First Street                    |                  |                     |
| <u>Bethlehem, Pennsylvania</u>           |                  | <u>18015-1360</u>   |
| (Address of Principal Executive Offices) |                  | (Zip Code)          |

Registrant's telephone number, including area code: 610-882-1820

## Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

On December 20, 2005, OraSure Technologies, Inc. (the Company ) issued a press release providing an update regarding an increased level of false positive results recently reported by specific clinical sites from the use of the Company's OraQuick *ADVANCE* Rapid HIV-1/2 Antibody Test with oral fluid. A copy of this press release is attached as Exhibit 99.1 to this Report and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits**

**(d) Exhibits**

| <b>Exhibit<br/>Number</b> | <b>Description</b>                    |
|---------------------------|---------------------------------------|
| 99.1                      | Press Release dated December 20, 2005 |

**Signatures**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: December 20, 2005

ORASURE TECHNOLOGIES, INC.

By: /s/ JACK E. JERRETT  
Jack E. Jerrett  
Senior Vice President, General Counsel  
and Secretary

**Index to Exhibits**

| <b><u>Exhibit<br/>Number</u></b> | <b><u>Description</u></b>             |
|----------------------------------|---------------------------------------|
| 99.1                             | Press Release dated December 20, 2005 |